These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11682563)

  • 1. In vitro activity of posaconazole against clinical isolates of dermatophytes.
    Barchiesi F; Arzeni D; Camiletti V; Simonetti O; Cellini A; Offidani AM; Scalise G
    J Clin Microbiol; 2001 Nov; 39(11):4208-9. PubMed ID: 11682563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method.
    Perea S; Fothergill AW; Sutton DA; Rinaldi MG
    J Clin Microbiol; 2001 Jan; 39(1):385-8. PubMed ID: 11136808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
    Gupta AK; Kohli Y; Batra R
    Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of terbinafine against clinical isolates of dermatophytes.
    Arzeni D; Barchiesi F; Compagnucci P; Cellini A; Simonetti O; Offidani AM; Scalise G
    Med Mycol; 1998 Aug; 36(4):235-7. PubMed ID: 9776840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method.
    Bhatia VK; Sharma PC
    Indian J Med Microbiol; 2015; 33(4):533-7. PubMed ID: 26470960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
    Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
    Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis.
    Salehi Z; Fatahi N; Taran M; Izadi A; Badali H; Hashemi SJ; Rezaie S; Daie Ghazvini R; Ghaffari M; Aala F; Barac A; Khodavaisy S
    J Mycol Med; 2020 Jun; 30(2):100935. PubMed ID: 32139093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes.
    Tamura T; Asahara M; Yamamoto M; Yamaura M; Matsumura M; Goto K; Rezaei-Matehkolaei A; Mirhendi H; Makimura M; Makimura K
    Microbiol Immunol; 2014 Jan; 58(1):1-8. PubMed ID: 24215461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of in vitro methods to analyse the antifungal activity of propolis against yeasts isolated from patients with superficial mycoses.
    Silici S; Koc AN
    Lett Appl Microbiol; 2006 Sep; 43(3):318-24. PubMed ID: 16910939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.
    Ghannoum MA; Chaturvedi V; Espinel-Ingroff A; Pfaller MA; Rinaldi MG; Lee-Yang W; Warnock DW
    J Clin Microbiol; 2004 Jul; 42(7):2977-9. PubMed ID: 15243047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens.
    Cetinkaya Z; Kiraz N; Karaca S; Kulac M; Ciftci IH; Aktepe OC; Altindis M; Kiyildi N; Piyade M
    Eur J Dermatol; 2005; 15(4):258-61. PubMed ID: 16048753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole.
    Rincón S; Cepero de García MC; Espinel-Ingroff A
    J Clin Microbiol; 2006 Sep; 44(9):3429-31. PubMed ID: 16954293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
    Carrillo-Muñoz AJ; Giusiano G; Guarro J; Quindós G; Guardia C; del Valle O; Rodríguez V; Estivill D; Cárdenes CD
    Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis].
    Carrillo-Muñoz AJ; Cárdenes CD; Carrillo-Orive B; Rodríguez V; Del Valle O; Casals JB; Ezkurra PA; Quindós G
    Rev Iberoam Micol; 2005 Jun; 22(2):110-3. PubMed ID: 16107170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
    J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.